Shinhung Co (004080) Fair Value & Analysis
Healthcare · KR · Market cap 130B KRW
Fair value as of: Jul 22, 2026
From 15 valuation models · updated 19 days ago
Fair value updated Jul 22, 2026, revised from 8,988 KRW to 6,704 KRW (−25.4%) since Jun 25, 2026. Share price +0.8% over the past month.
A solid business, but screening 52% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (7,884 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 10,485 KRW – 16,755 KRW · fair‑value band 5,028 KRW – 7,884 KRW · the 14,050 KRW price screens above the 6,704 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Shinhung Co (004080) currently trades at 14,050 KRW, while our model-based Fair Value estimate is 6,704 KRW, implying the stock looks roughly 52.3% overvalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Shinhung Co generated revenue of 104B KRW at a net margin of 3.2%. Revenue grew 6.5% year over year. It earns a return on equity of 3.0%. Net debt stands at 8.9B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 5,028 KRW (bear case) to 7,884 KRW (bull case); at 14,050 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 4% below its 52-week high and 7% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -26% fair-value upside, at -52%, 004080 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: Asset-Based (8,347 KRW) versus Earnings-Based (2,533 KRW). Highest evidence: Residual Income (76).
Notify me when 004080 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 50 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shinhung Co., Ltd. manufactures, imports, and sells dental products and supplies in South Korea. Its products include implant systems; dental units and chairs; dental alloys, such as composition tables, crowns, and porcelain under the Goldenian brand name; prefabricates SS crowns; taurus, insert, and mobile cabinets; compressors and mixers; dental needles; …
Full company description
Shinhung Co., Ltd. manufactures, imports, and sells dental products and supplies in South Korea. Its products include implant systems; dental units and chairs; dental alloys, such as composition tables, crowns, and porcelain under the Goldenian brand name; prefabricates SS crowns; taurus, insert, and mobile cabinets; compressors and mixers; dental needles; dental porcelain powder and laboratory products; and disposable needles, dental operatories, and autoclaves and X-ray equipment. The company also offers loan services for dentists. Shinhung Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shinhung Co reported revenue of 103B KRW in FY2025 versus 127B KRW in FY2021, a compound −5.2%/yr. Reported net income was 2.8B KRW in FY2025, compounding −32.3%/yr from FY2021.
004080 screens 52% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| DexCom, Inc DXCM | $74.96 | $38.95 | -48% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
Compare Shinhung Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shinhung Co (004080) overvalued or undervalued?
What is the fair value of 004080?
What is the quality score of 004080?
What is the revenue of Shinhung Co (004080)?
What is the net profit margin of 004080?
Does Shinhung Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shinhung Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.